Group 1 - C4 Therapeutics Inc. (NASDAQ:CCCC) is recognized as one of the 11 most popular AI penny stocks to buy, with a price target increase from $20 to $30 by Brookline, reflecting growing confidence in the company's developments [1] - The Phase 2 MOMENTUM trial for cemsidomide, which has shown a differentiated safety and tolerability profile, is expected to support its use in second-line and later patient populations [2] - The first patient has been dosed in the Phase 2 MOMENTUM trial, which evaluates cemsidomide in combination with dexamethasone for relapsed or refractory multiple myeloma, building on previous positive results from the Phase 1 study [3][4] Group 2 - C4 Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel targeted protein degradation therapies aimed at treating cancer and other serious diseases [5] - The company has established strategic partnerships with notable firms such as Merck KGaA, Biogen, and Betta Pharmaceuticals, enhancing its development capabilities [5]